Literature DB >> 11859933

Gangliosides inhibit the release of interleukin-1beta in amyloid beta-protein-treated human monocytic cells.

T Ariga1, M Kiso, A Hasegawa, T Miyatake.   

Abstract

Amyloid-beta protein (A beta) is known to induce microglial activation with concomitant release of cytokines. Gangliosides have documented neuritogenic and neurotrophic properties. We determined the effects of A beta on the release of interleukin-1beta (IL-1beta) from the human monocytic cell line, THP-1 cells. A beta 1-42 significantly induced the release of IL-1beta from the cells. A beta 1-40, A beta 40-1, A beta 1-38, and A beta precursor protein (beta-APP) analogs also released a small amount of IL-1beta. A beta 1-42-activated cells demonstrated approx an 18-fold higher IL-1beta release than that for control cells or A beta 1-40 (soluble; S) treated cells. The release of IL-1beta from A beta 1-42-activated cells was significantly inhibited (33-48% of activated cells; p < 0.05 for the control value) by addition of gangliosides, suggesting that gangliosides inhibit the continuous cycle of the IL-1beta production in THP-1 cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11859933     DOI: 10.1385/JMN:17:3:371

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  34 in total

1.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

2.  Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles.

Authors:  L P Choo-Smith; W Garzon-Rodriguez; C G Glabe; W K Surewicz
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

3.  Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients.

Authors:  L E Augustinsson; K Blennow; C Blomstrand; G Bråne; R Ekman; P Fredman; I Karlsson; M Kihlgren; W Lehmann; A Lekman; J E Månsson; I Ramström; A Wallin; C Wikkelsö; C G Gottfries; L Svennerholm
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Jan-Feb       Impact factor: 2.959

4.  Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices.

Authors:  H Katsuki; S Nakai; Y Hirai; K Akaji; Y Kiso; M Satoh
Journal:  Eur J Pharmacol       Date:  1990-06-08       Impact factor: 4.432

5.  GM1 inhibits amyloid beta-protein-induced cytokine release.

Authors:  T Ariga; R K Yu
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

6.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor.

Authors:  J D Buxbaum; M Oishi; H I Chen; R Pinkas-Kramarski; E A Jaffe; S E Gandy; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors.

Authors:  G Ferrari; B L Anderson; R M Stephens; D R Kaplan; L A Greene
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

8.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Inhibition by gangliosides of the specific binding of lipopolysaccharide (LPS) to human monocytes prevents LPS-induced interleukin-1 production.

Authors:  J M Cavaillon; C Fitting; B Hauttecoeur; N Haeffner-Cavaillon
Journal:  Cell Immunol       Date:  1987-05       Impact factor: 4.868

10.  Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures.

Authors:  R Del Bo; N Angeretti; E Lucca; M G De Simoni; G Forloni
Journal:  Neurosci Lett       Date:  1995-03-16       Impact factor: 3.046

View more
  5 in total

1.  Exploring the mechanism of beta-amyloid toxicity attenuation by multivalent sialic acid polymers through the use of mathematical models.

Authors:  Christopher B Cowan; Dhara A Patel; Theresa A Good
Journal:  J Theor Biol       Date:  2009-02-13       Impact factor: 2.691

2.  Cytotoxic effects of G(M1) ganglioside and amyloid β-peptide on mouse embryonic neural stem cells.

Authors:  Makoto Yanagisawa; Toshio Ariga; Robert K Yu
Journal:  ASN Neuro       Date:  2010-03-15       Impact factor: 4.146

3.  Development of photocrosslinked sialic acid containing polymers for use in Abeta toxicity attenuation.

Authors:  Christopher B Cowan; Gerard L Coté; Theresa A Good
Journal:  Biomaterials       Date:  2008-06-03       Impact factor: 12.479

4.  Amyloid precursor protein mediated changes in intestinal epithelial phenotype in vitro.

Authors:  Kendra L Puig; Gunjan D Manocha; Colin K Combs
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  Anti-inflammatory role of GM1 and other gangliosides on microglia.

Authors:  Danny Galleguillos; Qian Wang; Noam Steinberg; Asifa Zaidi; Gaurav Shrivastava; Kamaldeep Dhami; Gour C Daskhan; Edward N Schmidt; Zoë Dworsky-Fried; Fabrizio Giuliani; Matthew Churchward; Christopher Power; Kathryn Todd; Anna Taylor; Matthew S Macauley; Simonetta Sipione
Journal:  J Neuroinflammation       Date:  2022-01-06       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.